How to buy Abiomed (ABMD) shares in the UK

Learn how to easily invest in Abiomed shares.

Abiomed Inc
+ $3.26 ( + 0.94%)

Abiomed Inc (ABMD) is a leading medical devices business based in the US. In the week up to 13 October Abiomed shares surged 9.94% to a closing position of $345.07. Over the last 12 months, Abiomed's share price has risen by 27.47% from $278.5. Abiomed is listed on the NASDAQ and employs 1,725 staff. All prices are listed in US Dollars.

How to buy shares in Abiomed

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: ABMD in this case.
  5. Research Abiomed shares. The platform should provide the latest information available.
  6. Buy your Abiomed shares. It's that simple.
The whole process can take as little as 15 minutes.

How has coronavirus impacted Abiomed's share price?

Since the stock market crash that started in February 2020, Abiomed's share price has had significant positive movement.

Its last market close was $349.68, which is 52.32% up on its pre-crash value of $166.74 and 193.82% up on the lowest point reached during the March 2020 crash when the shares fell as low as $119.0101.

If you had bought $1,000 worth of Abiomed shares at the start of February 2020, those shares would have been worth $711.99 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,881.28.

Abiomed share price (NASDAQ:ABMD)

Use our graph to track the performance of ABMD stocks over time.

Abiomed shares at a glance

Information last updated 2021-09-17.
Previous close$357.87
Change %-0.802%
Information last updated 2021-10-15.
52-week range$242.73 - $376.99
50-day moving average$348.5212
200-day moving average$323.385
Wall St. target price$387.33
PE ratio103.8941
Dividend yieldN/A (0%)
Earnings per share (TTM)$3.382
eToro Free Stocks

Invest in Abiomed shares with 0% commission

Other fees apply. Your capital is at risk.

  • Unlimited trades, with no dealing charges or management fees
  • Pay no stamp duty on UK shares (saving 0.5%)
  • Create an account today in a few minutes
Capital at risk

Fees for buying 5x Abiomed shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
Freetrade logo £0 No minimum £5.79
£1,292.31 total
Capital at risk
eToro Free Stocks logo £0 $50 £6.43
£1,292.95 total
Capital at risk
Fineco logo £0 No minimum £12.87
£1,299.39 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £1.72
£1,288.24 total
Capital at risk
Stake logo £0 £50 £6.45
£1,292.97 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £24.83
£1,311.35 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £27.30
£1,313.82 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £25.60
£1,312.12 total
Capital at risk

Full comparison of share dealing platforms

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is it a good time to buy Abiomed stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Abiomed price performance over time

Historical closes compared with the last close of $355

1 week (2021-10-14) 2.88%
1 month (2021-09-22) 1.73%
3 months (2021-07-22) 9.72%
6 months (2021-04-22) 3.38%
1 year (2020-10-22) 27.47%
2 years (2019-10-22) 107.81%
3 years (2018-10-22) -3.06%
5 years (2016-10-21) 184.34%

Is Abiomed under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

P/E ratio

Abiomed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 104x. In other words, Abiomed shares trade at around 104x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, Abiomed's P/E ratio is best considered in relation to those of others within the medical devices industry or those of similar companies.

PEG ratio

Abiomed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.75. Higher PEG ratios such as this can be interpreted as meaning the shares offer worse value given the current rate of growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abiomed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

However, it's sensible to consider Abiomed's PEG ratio in relation to those of similar companies.


Abiomed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $289.8 million (£0.0 million).

The EBITDA is a measure of a Abiomed's overall financial performance and is widely used to measure a its profitability.

To put that into context you can compare it against similar companies.


Revenue TTM $935.3 million
Operating margin TTM 28.34%
Gross profit TTM $685.6 million
Return on assets TTM 12.24%
Return on equity TTM 12.82%
Profit margin 16.51%
Book value $28.814
Market capitalisation $15.9 billion

TTM: trailing 12 months

How to short and sell Abiomed shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "ABMD.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 826,932 Abiomed shares held short by investors – that's known as the "short interest". This figure is 1.1% down from 836,313 last month.

There are a few different ways that this level of interest in shorting Abiomed shares can be evaluated.

Short interest ratio (SIR)

Abiomed's "short interest ratio" (SIR) is the quantity of Abiomed shares currently shorted divided by the average quantity of Abiomed shares traded daily (recently around 189663.30275229). Abiomed's SIR currently stands at 4.36. In other words for every 100,000 Abiomed shares traded daily on the market, roughly 4360 shares are currently held short.

To gain some more context, you can compare Abiomed's short interest ratio against those of similar companies.

However Abiomed's short interest can also be evaluated against the total number of Abiomed shares, or, against the total number of tradable Abiomed shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Abiomed's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Abiomed shares in existence, roughly 20 shares are currently held short) or 0.0186% of the tradable shares (for every 100,000 tradable Abiomed shares, roughly 19 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Abiomed.

Find out more about how you can short Abiomed stock.

Abiomed share dividends

We're not expecting Abiomed to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

You may also wish to consider:

Have Abiomed's shares ever split?

Abiomed's shares were split on a 2:1 basis on 1 October 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Abiomed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Abiomed shares which in turn could have impacted Abiomed's share price.

Share price volatility

Over the last 12 months, Abiomed's shares have ranged in value from as little as $242.73 up to $376.99. A popular way to gauge a stock's volatility is its "beta".

ABMD.US volatility(beta: 1.35)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abiomed's is 1.3492. This would suggest that Abiomed's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put Abiomed's beta into context you can compare it against those of similar companies.

Win £500 to get your trading started

Subscribe to trending stock alerts for a chance to win

By submitting, you agree to the Finder Privacy and Cookies Policy and Terms of Use

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site